Wedbush Downgrades Poniard Pharmaceuticals (PARD) to Underperform; Picoplatin SPEAR Phase III Study Fails
Tweet Send to a Friend
Wedbush downgrades Poniard Pharmaceuticals Inc. (Nasdaq: PARD) from Outperform to Underperform.
Wedbush analyst says, "Poniard announced that the SPEAR Phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wedbush analyst says, "Poniard announced that the SPEAR Phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
